secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001437749-22-026595
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Q3 revenue $40.7M (+21% YoY); biopreservation media +50%; tightens FY22 guidance to $160-164M
--------------------------------------------------------------------------------

- GAAP net loss of $10.0M ($0.23 loss per share) vs net income of $79K in Q3 2021.
- Adjusted EBITDA turned positive at $1.4M versus negative $2.1M in Q3 2021.
- Cell Processing platform revenue $18.1M (+57% YoY); Freezer/Thaw Systems $15.3M (-13% YoY).
- Cash, equivalents and marketable securities $62.1M; borrowed $20M via term loan in Q3.
- FY2022 revenue guidance narrowed to $160-164M from $160-166M; organic growth expected 37-40%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000143774922026595/0001437749-22-026595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000143774922026595/bioli20221109_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-026595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer